Sugi Predict

Sugi Predict / Compounds / SCHEMBL155135

SCHEMBL155135

SCHEMBL155135

COC(=O)c1cc(Br)ccc1C(F)(F)F

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 2/20 0.58
▸ CFTR P13569 4/20 0.48
▸ NR4A2 P43354 1/20 0.48
▸ GAA P10253 2/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ CES2 O00748 1/20 0.46
▸ SOS1 Q07889 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ SLC6A3 Q01959 1/20 0.43
▸ TMPRSS4 Q9NRS4 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ MBOAT4 Q96T53 1/20 0.40
▸ CHEK1 O14757 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30736877 1.00 NOTUM (0.58) NOTUMCFTRNR4A2GAAALDH1A1
SCHEMBL23791810 0.89 NOTUM (0.49) NOTUMCFTRNR4A2GAAALDH1A1
SCHEMBL516822 0.87 NOTUM (0.54) NOTUMCFTRNR4A2GAAALDH1A1
SCHEMBL18159377 0.81 CYP46A1 (0.53) NOTUMCFTRNR4A2GAACES2
SCHEMBL1995951 0.81 CES2 (0.71) NOTUMCFTRALDH1A1CES2HSD17B10
SCHEMBL696154 0.81 NOTUM (0.51) NOTUMCFTRALDH1A1CES2SOS1
SCHEMBL24436898 0.81 CA12 (0.61) NOTUMCFTRGAACES2SOS1
SCHEMBL22716761 0.81 NR4A2 (0.46) NOTUMNR4A2GAAALDH1A1SMN1; SMN2
SCHEMBL28021177 0.80 CYP1A2 (0.53) NOTUMGAAALDH1A1CES2TMPRSS4
SCHEMBL2482051 0.80 NR4A2 (0.54) NR4A2GAAALDH1A1CES2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12595239-B2 Substituted isoxazoline derivatives BASF SE (DE) 2026-04-07 — — US disclosed
EP-4291551-B1 SUBSTITUTED ISOXAZOLINE DERIVATIVES BASF SE (DE) 2025-08-13 — — EP disclosed
US-20240287060-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-08-29 — — US disclosed
US-20240140917-A1 SUBSTITUTED ISOXAZOLINE DERIVATIVES BASF SE (DE) 2024-05-02 — — US disclosed
WO-2024026486-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-02-01 — — WO disclosed
EP-4301752-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF Cambridge Enterprise Limited (GB) 2024-01-10 — — EP disclosed
US-11866436-B2 Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-01-09 — — US disclosed
CN-117295736-A Benzo [ C ] [2,6] naphthyridine derivatives, compositions thereof and therapeutic uses thereof 剑桥实业有限公司 2023-12-26 — — CN disclosed
EP-4291551-A1 SUBSTITUTED ISOXAZOLINE DERIVATIVES BASF SE (DE) 2023-12-20 — — EP disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 — — US disclosed
US-8202984-B2 Glucopyranoside compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-06-19 — — US disclosed
US-20120058941-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-03-08 — — US disclosed
WO-2011159067-A2 THIAZOLE DERIVATIVES AS SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2011-12-22 — — WO disclosed
US-7943788-B2 Including the antidiabetic, antiobesity sodium glucose transport inhibitor Canagliflozin (1-( beta -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-17 — — US disclosed
US-20110105424-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-05 — — US disclosed
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2009-10-29 — — US disclosed
CN-1829729-A Novel compounds TANABE SEIYAKU CO (JP) 2006-09-06 — — CN disclosed
EP-1651658-A1 NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER TANABE SEIYAKU CO., LTD. (JP) 2006-05-03 — — EP disclosed
US-20050233988-A1 Novel compounds TANABE SEIYAKU CO., LTD. (JP) 2005-10-20 — — US disclosed
WO-2005012326-A1 NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER TANABE SEIYAKU CO., LTD. (JP) 2005-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058941-A1 GLUCOPYRANOSIDE COMPOUND UGGT1, B3GAT3, FUT6 NOTUM 2268/4885CFTR 2743/4885NR4A2 349/4885
US-20050233988-A1 Novel compounds CYP1B1, CYP4B1, CYP2B6 NOTUM 1133/4885CFTR 1128/4885NR4A2 483/4885
US-12595239-B2 Substituted isoxazoline derivatives CBR3, ADRA2C, CYP4Z1 NOTUM 3157/4885CFTR 2743/4885NR4A2 675/4885
US-20110105424-A1 GLUCOPYRANOSIDE COMPOUND UGGT1, B3GAT3, FUT6 NOTUM 2268/4885CFTR 2743/4885NR4A2 349/4885
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 NOTUM 3220/4885CFTR 4043/4885NR4A2 3550/4885
US-20240140917-A1 SUBSTITUTED ISOXAZOLINE DERIVATIVES CYP4X1, PRDX5, PRDX1 NOTUM 1805/4885CFTR 3331/4885NR4A2 1853/4885
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH MAP3K1, MAP3K15, MAP3K5 NOTUM 3709/4885CFTR 4140/4885NR4A2 1393/4885
US-11866436-B2 Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof ABCB11, CEL, NDC1 NOTUM 392/4885CFTR 146/4885NR4A2 1162/4885
US-20240287060-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF CSNK1A1, CSNK1D, CSNK2A1 NOTUM 3816/4885CFTR 3916/4885NR4A2 210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.